The cholesterol-lowering drug atorvastatin (Lipitor) offers significant benefits guarding against heart attacks and strokes among patients with diabetes. The Collaborative Atorvastatin Diabetes Study (CARDS) is the largest study of statin use in patients with diabetes, involving more than 2800 patients with type 2 diabetes, no history of heart disease, and relatively low levels of cholesterol.
Among those patients taking atorvastatin, there was a 37% reduction in major cardiovascular events, and 48% fewer patients taking atorvastatin experienced strokes, compared with those taking placebo. In fact, atorvastatin proved so effective that the study was stopped 2 years early. This was the second time a study of atorvastatin was stopped early because of significant cardiovascular benefits. The number of cases of type 2 diabetes is increasing at an epidemic level, which researchers attribute to genetics, obesity, and lack of exercise.
The Oncology Care Pharmacist in Health-System Pharmacy
According to the National Cancer Institute, almost 40% of men and women will be given a diagnosis of some form of cancer in their lifetime.
News from the year's biggest meetings
Clinical features with downloadable PDFs